This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kabelitz, D. Articles by He, W. Search for Related Content PubMed PubMed Citation Articles by Kabelitz, D. Articles by He, W. Related Collections Cancer Immunology Cancer Immunology: Innate Immunity

Perspectives of T Cells in Tumor Immunology

¹ Institute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany and ² Department of Immunology, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, P.R. China

Requests for reprints: Dieter Kabelitz, Institute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, Michaelisstr. 5, D-24105 Kiel, Germany. Phone: 49-431-5973340; Fax: 49-431-5973335; E-mail: kabelitz{at}immunologie.uni-kiel.de.

Subsets of human T cells recognize tumor cell–expressed ligands that are not seen by the T-cell receptor of conventional ß T cells. V1 T cells recognize MHC class I chain–related molecules A and B and UL-16–binding proteins expressed at variable levels on epithelial tumor cells and some leukemias and lymphomas. In addition, therapeutically used aminobisphosphonates and synthetic phosphoantigens activate V2 T cells, the dominant subset of T cells in human peripheral blood that display strong cytotoxicity towards various epithelial tumors. Intentional activation of T cells in vivo and/or adoptive cell therapy with in vitro expanded T cells holds considerable promise as a novel immunotherapy in certain types of cancer. [Cancer Res 2007;67(1):5–8]

This article has been cited by other articles:

				G. Gruenbacher, H. Gander, A. Rahm, W. Nussbaumer, N. Romani, and M. Thurnher CD56+ human blood dendritic cells effectively promote TH1-type {gamma}{delta} T-cell responses Blood, November 12, 2009; 114(20): 4422 - 4431. [Abstract] [Full Text] [PDF]

				Y. Wu, W. Wu, W. M. Wong, E. Ward, A. J. Thrasher, D. Goldblatt, M. Osman, P. Digard, D. H. Canaday, and K. Gustafsson Human {gamma}{delta} T Cells: A Lymphoid Lineage Cell Capable of Professional Phagocytosis J. Immunol., November 1, 2009; 183(9): 5622 - 5629. [Abstract] [Full Text] [PDF]

				Q. Qi, M. Xia, J. Hu, E. Hicks, A. Iyer, N. Xiong, and A. August Enhanced development of CD4+ {gamma}{delta} T cells in the absence of Itk results in elevated IgE production Blood, July 16, 2009; 114(3): 564 - 571. [Abstract] [Full Text] [PDF]

				J. Li, M. J. Herold, B. Kimmel, I. Muller, B. Rincon-Orozco, V. Kunzmann, and T. Herrmann Reduced Expression of the Mevalonate Pathway Enzyme Farnesyl Pyrophosphate Synthase Unveils Recognition of Tumor Cells by V{gamma}9V{delta}2 T Cells J. Immunol., June 15, 2009; 182(12): 8118 - 8124. [Abstract] [Full Text] [PDF]

				M. Todaro, M. D'Asaro, N. Caccamo, F. Iovino, M. G. Francipane, S. Meraviglia, V. Orlando, C. La Mendola, G. Gulotta, A. Salerno, et al. Efficient Killing of Human Colon Cancer Stem Cells by {gamma}{delta} T Lymphocytes J. Immunol., June 1, 2009; 182(11): 7287 - 7296. [Abstract] [Full Text] [PDF]

				J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies Blood, May 14, 2009; 113(20): 4875 - 4884. [Abstract] [Full Text] [PDF]

				C. Devaud, E. Bilhere, S. Loizon, V. Pitard, C. Behr, J.-F. Moreau, J. Dechanet-Merville, and M. Capone Antitumor Activity of {gamma}{delta} T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model Cancer Res., May 1, 2009; 69(9): 3971 - 3978. [Abstract] [Full Text] [PDF]

				J.-J. Lataillade, O. Pierre-Louis, H. C. Hasselbalch, G. Uzan, C. Jasmin, M.-C. Martyre, M.-C. Le Bousse-Kerdiles, and on behalf of the French INSERM and the European EU Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence Blood, October 15, 2008; 112(8): 3026 - 3035. [Abstract] [Full Text] [PDF]

				H. Chen, X. He, Z. Wang, D. Wu, H. Zhang, C. Xu, H. He, L. Cui, D. Ba, and W. He Identification of Human T Cell Receptor {gamma}{delta}-recognized Epitopes/Proteins via CDR3{delta} Peptide-based Immunobiochemical Strategy J. Biol. Chem., May 2, 2008; 283(18): 12528 - 12537. [Abstract] [Full Text] [PDF]

				Z. Liu, I.-E. A. Eltoum, B. Guo, B. H. Beck, G. A. Cloud, and R. D. Lopez Protective Immunosurveillance and Therapeutic Antitumor Activity of {gamma}{delta} T Cells Demonstrated in a Mouse Model of Prostate Cancer J. Immunol., May 1, 2008; 180(9): 6044 - 6053. [Abstract] [Full Text] [PDF]

				J. Holderness, L. Jackiw, E. Kimmel, H. Kerns, M. Radke, J. F. Hedges, C. Petrie, P. McCurley, P. M. Glee, A. Palecanda, et al. Select Plant Tannins Induce IL-2R{alpha} Up-Regulation and Augment Cell Division in {gamma}{delta} T Cells J. Immunol., November 15, 2007; 179(10): 6468 - 6478. [Abstract] [Full Text] [PDF]

				F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia, G. Cicero, A. Roberts, S. Buccheri, M. D'Asaro, N. Gebbia, et al. Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer Cancer Res., August 1, 2007; 67(15): 7450 - 7457. [Abstract] [Full Text] [PDF]